$0.76
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 797 full-time employees. The firm has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. The company engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Country

US

CEO

Dr. Karen Noblett

IPO date

2018

Employees

797

ISIN

US05465P1012

Key stats

Open

$0.76

Volume

238.16K

Market cap

$6.85M

Prev. close

$0.76

Impl / hst vl

-

Open interest

$0.00

$0.75

Day’s Range

$0.76

$0.25

52W Range

$4.42

Valuation

55
Valuation score
Fairly Valued
P/E
-
P/S
0.02
P/B
0.01
Current ratio
8.16
Debt / Equity
-0.36
ROE
-0.88%
Gross margin
77.16%
Income growth
-100.30%
FCF growth
-115.22

Analysts estimates

Consensus rating
Hold

The average rating from top 13 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$73.33
The top 11 analysts forecasts that 12-month price may increase by 9,548.25%, with a low of $71.71 and a high of $78.75
$71.71
Low
$73.33
Avg
$78.75
High
Current price

Earnings

Q3 ‘24 revenue
$116.19M
Q3 ‘24 net income
-$21.00K
Revenue
Net income
Previous EPS
$0.13
Estimate EPS
$0.14
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply